Publication | Closed Access
A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
72
Citations
23
References
2010
Year
Lapatinib was well tolerated but like other EGFR- and HER2-targeted agents in advanced HRPC failed to show significant antitumor activity even in this very early stage hormonally untreated population.
| Year | Citations | |
|---|---|---|
Page 1
Page 1